Biotechnology company Nuclera has extended its Series C financing to $87 million to advance antibody engineering.  The financing round, led by Elevage Medical Technologies and Jonathan Milner, was extended by $12 million following earlier investment worth $75 million.  The funding is set to support Nuclera’s development of eProtein discovery for full-format antibody expression, purification and binding validation.  Expanding eProtein Discovery with antibody-specific capabilities represents a strategic step […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!